

### This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
<b>Cancer</b>				
Brain cancer	Hedgehog pathway; P glycoprotein (MDR1; ABCB1; P-gp; CD243)	<p>Mouse studies suggest P-gp inhibitors could help reverse resistance to saridegib in medulloblastoma. In a mouse model of aggressive medulloblastoma, the hedgehog pathway inhibitor saridegib decreased tumor size and increased survival compared with vehicle. In the model, hedgehog pathway signaling rebounded and levels of P-gp, a transporter for which saridegib is a known substrate, increased after six weeks of treatment. In the same model, saridegib plus the P-gp inhibitor verapamil reversed the drug resistance seen at six weeks. Next steps could include testing a P-gp inhibitor plus saridegib in clinical trials for medulloblastoma.</p> <p>Infinity Pharmaceuticals Inc.'s saridegib is in Phase II trials to treat bone cancer and myeloproliferative disorder and is in preclinical development for non-small cell lung cancer (NSCLC).</p> <p>Verapamil is a generic calcium channel blocker approved for multiple cardiovascular indications.</p> <p><b>SciBX 5(19); doi:10.1038/scibx.2012.489</b>  <b>Published online May 10, 2012</b></p>	Unpatented; licensing status not applicable	<p>Lee, M.J. <i>et al. Proc. Natl. Acad. Sci. USA</i>; published online May 1, 2012; doi:10.1073/pnas.1114718109</p> <p><b>Contact:</b> James M. Olson, Fred Hutchinson Cancer Research Center, Seattle, Wash.  e-mail: <a href="mailto:jolson@fhcrc.org">jolson@fhcrc.org</a></p>